TY - JOUR
T1 - Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system
T2 - An in vitro method of screening new drugs
AU - Fan, Dominic
AU - Ajani, Jaffer A.
AU - Baker, Fraser L.
AU - Tomasovic, Barbara
AU - Brock, William A.
AU - Spitzer, Gary
N1 - Funding Information:
Accepted 7 May 1987. This work was supported by Contract JMV:bg 11783 from LifeTrac Ltd., Irvine, CA, U.S.A. and by allotments from the Susan G. Komen Foundation and from the Physicians’ Referral Servicr. Address reprint requests to: Gary Spitzer, M.D. Anderson Hospital and Tumor Institute, 1515 Holcombe Blvd., Box 47, Houston, Texas 77030, U.S.A.
PY - 1987/10
Y1 - 1987/10
N2 - We compared the in vitro growth inhibition of primary human tumor cells in the adhesive tumor cell culture system (ATCCS), exposed to the investigational agents caracemide, spirogermanium and taxol and to standard chemotherapy agents at equitoxic concentrations for granulocyte-macrophage colony-forming cells (GM-CFC) in vitro. Clinically active standard agents tested at up to GM-CFC 90% inhibitory concentrations (ic90) resulted in in vitro activity (≥ 50% tumor growth inhibition) in at least 30% of tumors tested. In vitro responses for taxol, caracemide and spirogermanium were 78%, 9% and 7%, respectively. This paper proposes a model that incorporates two hypotheses: (1) myelotoxic drugs which inhibit tumor growth at concentrations equal to or less than equitoxic GM-CFC ics will demonstrate clinical activity; and (2) both myelotoxic and particular nonmyelotoxic drugs inactive in vitro at these doses will not be active clinically. If this drug screening concept is valid, taxol may be clinically more active than caracemide and spirogermanium.
AB - We compared the in vitro growth inhibition of primary human tumor cells in the adhesive tumor cell culture system (ATCCS), exposed to the investigational agents caracemide, spirogermanium and taxol and to standard chemotherapy agents at equitoxic concentrations for granulocyte-macrophage colony-forming cells (GM-CFC) in vitro. Clinically active standard agents tested at up to GM-CFC 90% inhibitory concentrations (ic90) resulted in in vitro activity (≥ 50% tumor growth inhibition) in at least 30% of tumors tested. In vitro responses for taxol, caracemide and spirogermanium were 78%, 9% and 7%, respectively. This paper proposes a model that incorporates two hypotheses: (1) myelotoxic drugs which inhibit tumor growth at concentrations equal to or less than equitoxic GM-CFC ics will demonstrate clinical activity; and (2) both myelotoxic and particular nonmyelotoxic drugs inactive in vitro at these doses will not be active clinically. If this drug screening concept is valid, taxol may be clinically more active than caracemide and spirogermanium.
UR - http://www.scopus.com/inward/record.url?scp=0023426159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023426159&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(87)90088-5
DO - 10.1016/0277-5379(87)90088-5
M3 - Article
C2 - 2890527
AN - SCOPUS:0023426159
SN - 0277-5379
VL - 23
SP - 1469
EP - 1476
JO - European Journal of Cancer and Clinical Oncology
JF - European Journal of Cancer and Clinical Oncology
IS - 10
ER -